ULOQ [Study As­sess­ment]

posted by Anand – India, 2017-10-30 07:38 (1976 d 00:33 ago) – Posting: # 17945
Views: 8,732

Dear All,

Request to clarify,

In our Pivotal BE Study ULOQ was observed, whether we should exclude from PK?
After Dilution also it found ULOQ.
Method should be redeveloped or revalidated?
If included,What justification we should provide to Regulatory Agency?

Thanks in advance.

Regards,
A.A


Edit: Category changed; see also this post #1. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,557 posts in 4,724 threads, 1,607 registered users;
17 visitors (0 registered, 17 guests [including 8 identified bots]).
Forum time: 09:12 CEST (Europe/Vienna)

The function of genius is not to give new answers, but to pose
new questions which time and mediocrity can resolve.    H.R. Trevor-Roper

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5